Upload Image (Max 20MB per Image)
Israeli pharmaceutical company Protalix BioTherapeutics has announced initial positive results from its Phase I clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112), in patients with Gaucher disease. In the trial, oral ...
Tags: Protalix, Oral GCD